Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNDX-5613 in Patients With Colorectal Cancer and Other Solid Tumors

NCT05731947 is registered in ClinicalTrials.gov with Syndax Pharmaceuticals as lead sponsor.

NCT NCT05731947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05731947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNDX-5613 in Patients With Colorectal Cancer and Other Solid Tumors
Lead sponsor
Syndax Pharmaceuticals
Phase
Phase 1/2
Overall status
Terminated
Start date
April 4, 2023
Completion date
June 30, 2025
Enrollment
41 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, solid tumors